Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized study of OVX836 influenza vaccine versus Influvac Tetra in healthy adults
2019-002939-28Phase 2Completed
- Sponsor
- Osivax
- Start
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of OVX836 in influenza (3 arms), sponsored by Osivax. Primary endpoint: Safety endpoint. Started Oct 2019; status: completed.
02
Drugs
OVX836
03
Conditions
influenza
Beyond the preview
Go deeper on 2019-002939-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002939-28.